Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$2.05B |
| 2 |
Texas Instruments
TXN
|
+$1.69B |
| 3 |
NVIDIA
NVDA
|
+$1.36B |
| 4 |
Starbucks
SBUX
|
+$1.2B |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$949M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$2.77B |
| 2 |
Microsoft
MSFT
|
+$1.3B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.22B |
| 4 |
iShares US Real Estate ETF
IYR
|
+$1.11B |
| 5 |
Procter & Gamble
PG
|
+$915M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.33% |
| 2 | Consumer Discretionary | 7.25% |
| 3 | Financials | 7.18% |
| 4 | Communication Services | 6.16% |
| 5 | Healthcare | 5.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4051
Fennec Pharmaceuticals
FENC
$332M
| $51.1K | ﹤0.01% |
8,368
-4,508
| -35% | -$37.4K |
|
4052
CALL
Williams Companies
WMB
$86.7B
| $51K | ﹤0.01% |
1,200
-49,500
| -98% | -$1.99M |
|
|
NBP
4053
NovaBridge Biosciences American Depositary Shares
NBP
$185M
| $50.7K | ﹤0.01% |
30,370
-8,182
| -21% | -$14.6K |
|
4054
Inhibrx
INBX
$1.21B
| $50.7K | ﹤0.01% |
+3,579
| New | +$55.9K |
|
|
GOCO
4055
DELISTED
GoHealth
GOCO
| $50.6K | ﹤0.01% |
5,208
-1,325
| -20% | -$13.1K |
|
|
NEXN
4056
Nexxen International
NEXN
$579M
| $50.6K | ﹤0.01% |
9,000
| – | – |
|
4057
Medallion Financial
MFIN
$234M
| $50.3K | ﹤0.01% |
6,555
-17,380
| -73% | -$138K |
|
|
VTYX
4058
DELISTED
Ventyx Biosciences
VTYX
| $49.7K | ﹤0.01% |
21,519
-11,487
| -35% | -$47.7K |
|
4059
Alto Ingredients
ALTO
$367M
| $49.5K | ﹤0.01% |
34,253
-85,379
| -71% | -$148K |
|
4060
Bel Fuse Inc Class A
BELFA
$3.03B
| $49.4K | ﹤0.01% |
610
-5,464
| -90% | -$412K |
|
|
PRPH
4061
DELISTED
ProPhase Labs
PRPH
| $49.2K | ﹤0.01% |
+1,177
| New | +$61.7K |
|
|
ADAP
4062
DELISTED
Adaptimmune Therapeutics
ADAP
| $48.8K | ﹤0.01% |
50,061
| – | – |
|
4063
InfuSystem Holdings
INFU
$189M
| $48.8K | ﹤0.01% |
7,140
-6,074
| -46% | -$44.6K |
|
4064
iShares MSCI Poland ETF
EPOL
$732M
| $48.7K | ﹤0.01% |
1,985
| – | – |
|
4065
iShares Asia 50 ETF
AIA
$4.65B
| $48.7K | ﹤0.01% |
725
| – | – |
|
4066
Stratus Properties
STRS
$158M
| $48.5K | ﹤0.01% |
1,924
-1,993
| -51% | -$46.9K |
|
4067
Tilray
TLRY
$651M
| $48.4K | ﹤0.01% |
2,915
-13,778
| -83% | -$265K |
|
|
ELEV
4068
DELISTED
Elevation Oncology
ELEV
| $48.4K | ﹤0.01% |
+17,910
| New | +$67.4K |
|
4069
NN Inc
NNBR
$274M
| $48.3K | ﹤0.01% |
+16,116
| New | +$56.4K |
|
4070
iShares MSCI Philippines ETF
EPHE
$145M
| $48.2K | ﹤0.01% |
+1,994
| New | +$50.4K |
|
4071
American Well
AMWL
$183M
| $47.9K | ﹤0.01% |
7,368
-4,931
| -40% | -$49.6K |
|
4072
Astera Labs
ALAB
$54.6B
| $47.7K | ﹤0.01% |
788
-4,112
| -84% | -$285K |
|
|
SBT
4073
DELISTED
Sterling Bancorp, Inc. Common Stock
SBT
| $47.5K | ﹤0.01% |
9,089
-6,291
| -41% | -$31K |
|
4074
Paysign
PAYS
$513M
| $47.5K | ﹤0.01% |
11,019
-11,720
| -52% | -$51.7K |
|
4075
iShares MSCI EAFE Value ETF
EFV
$29B
| $47.2K | ﹤0.01% |
890
-18,046
| -95% | -$981K |
|
Similar funds
Barclays's Q2 2024 Portfolio in Review
As of Q2 2024, Barclays held 5,455 positions worth $327B, up 14% from $288B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Barclays deployed $29.4B of net new capital in Q2 2024, opening 406 new positions and adding to 1,053 existing holdings. Its largest new stake was Ferrovial N.V. Ordinary Shares: 4,837,593 shares worth $186M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 24% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was Apple, an estimated $2.77B trimmed.
- Barclays's largest Q2 2024 buy was Ferrovial N.V. Ordinary Shares: 4,837,593 shares worth $186M.
- Barclays added most to CRH in Q2 2024, an estimated $2.05B increase.
- Barclays's biggest Q2 2024 reduction was Apple, cutting an estimated $2.77B.
- Barclays fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $212M.
- Barclays's ten largest holdings make up 42% of its $327B portfolio in Q2 2024.
- Barclays opened 406 new positions and closed 646 in Q2 2024.
- Barclays's portfolio value rose 14% quarter-over-quarter to $327B.
Based on Barclays's 13F filing for Q2 2024, filed 14 Aug 2024.